Kopran Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/SNSE
₹263.16
-3.89-1.46% (1D)
As on 20 Nov 2026 at 15:59
As of 20 Nov 2026 at 15:59, Kopran Ltd is trading at ₹263.16. The 52-week range stands at ₹107.00–₹295.83, with a market cap of ₹1.27 thousand crore. At a P/E of 28.93 and a dividend yield of 1.14%, it is a small-cap stock in the Pharmaceuticals sector.

KOPRAN Price Chart

Market Cap
₹1.27K Cr
PE Ratio
28.93
ROCE
11.86%

Kopran Ltd Performance

Kopran Ltd Fundamentals

Know More
Market Cap₹1.27K Cr
ROE9.81%
P/E Ratio (TTM)28.93
EPS (TTM)₹9.08
P/B Ratio2.84
Dividend Yield1.14%
Industry P/E91.72
Book Value₹92.57
Debt to Equity0.18
Face Value₹10

Kopran Ltd Shareholding Pattern

Know More
Promoter41.8%
Foreign Institutions0.9%
Mutual Funds0%
Domestic Institutions0%
Public57.3%

Kopran Ltd Financial Statements

Know More
No data for this view.

Kopran Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Kopran

Kopran Limited was incorporated on April 26, 1958. The Company was promoted by the Somani group and is a group company of Parijat Enterprises. Company operates in two distinct business verticals. Company specialise in developing and manufacturing Penicillin and non-penicillin-based drugs. Leveraging cutting-edge technology, it manufactures highquality finished dosage drugs that adhere to international requirements. Kopran is one of the key contributors in the manufacturing and sale of diverse active pharmaceutical ingredients and advanced intermediates. The range of APIs manufactured by the Company includes Sterile Cephalosporins and Carbapenems. The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran's high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce. The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda. The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002. The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres. The company has also increased its installed capacity of Tablets & Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos). In Feb. 2001, Kopran tied up with E-Merck for co-marketing a new anti-inflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fast-moving non-steroid anti-inflammatory drugs (NSAID), has been launched in the international market. The Company also launched Cholestat (Atorvastatin - a cholesterol reducer) and further gave co-marketing rights for Atorvastatin to E-Merck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004. Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007. The Company during the FY 2014-15 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015. In FY 2023, the Company filed process patent applications for Nitroxoline in India, the EU and China. It received process patent for Nitroxoline in India and registered Nitroxoline in Germany. 14 new products launched during the year 2023. The Company further undertook the expansion of the multi-product plant at the Mahad facility to manufacture new molecules in 2024. The Scheme of Amalgamation between Kopran Laboratories Limited and the Company has been approved in the Board Meeting held on March 20, 2025.

Parent Organisation—
Founded1958
Managing DirectorSurendra Somani
NSE SymbolKOPRAN

Kopran Ltd Resistance and Support levels

R3275.94R2272.78R1270.82S1264.49S2262.53S3259.36263.16

Kopran Ltd Technicals

Current Price
₹263.16 ₹3.89 (-1.46%)
Bearish
6
Bullish
6
  • 20 Day0.5%
  • 50 Day3.2%
  • 100 Day11.8%
  • 200 Day25.1%

Kopran Ltd Latest News

View More
26 OCT 2026 | Monday
Kopran Limited to review Q2 financial results at a board meeting next Tuesday
12 OCT 2026 | Monday
Kopran Limited confirms compliance with SEBI regulations for the quarter ended September 30, 2026
25 SEPT 2026 | Friday
Kopran Limited closes trading window for insiders ahead of Q2 financial results
16 SEPT 2026 | Wednesday
Kopran Limited’s committee approved allotment of shares to employees under ESOP 2023
23 JUL 2026 | Thursday
Kopran to hold board meeting
17 JUL 2026 | Friday
Kopran to conduct AGM

2026

Annual ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Annual ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Kopran Ltd is ₹263.16 as of 20 Nov 2026 at 15:59.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now